Atrial fibrillation and thromboembolic stroke

Area of Science:

• Cardiology
• Neurology
• Pharmacology

Background:

• Atrial fibrillation (AF) is a common arrhythmia associated with a high risk of thromboembolic stroke.
• Effective anticoagulation strategies are crucial for stroke prevention in AF patients.
• Current guidelines recommend tailored approaches based on patient risk factors and comorbidities.

Purpose of the Study:

• To outline evidence-based recommendations for anticoagulation and rate control in patients with atrial fibrillation.
• To differentiate treatment strategies based on AF type, patient age, and specific risk factors.
• To provide guidance on the use of warfarin, aspirin, and rate-controlling medications.

Main Methods:

• Review of existing clinical guidelines and landmark studies on anticoagulation in atrial fibrillation.
• Analysis of patient subgroups including those with valvular heart disease, nonvalvular AF, and lone AF.
• Evaluation of pharmacological agents for rate control and rhythm management.

Main Results:

• Long-term oral warfarin is indicated for AF patients with a history of systemic embolism, mitral valve disease, nonvalvular AF, or mitral annular calcium to reduce thromboembolic stroke.
• Aspirin (325 mg/d) is an alternative for nonvalvular AF patients with warfarin contraindications or low thromboembolic risk if younger than 75.
• Elderly patients with lone AF should receive low-dose warfarin; younger lone AF patients (<60 years) should not receive anticoagulants.
• Rate control can be achieved with digoxin, verapamil, diltiazem, and propranolol.
• Antiarrhythmic drugs are not routinely recommended, but propranolol may be used for ventricular arrhythmias or post-conversion.

Conclusions:

• Anticoagulation choice in atrial fibrillation requires careful consideration of individual patient risk factors and contraindications.
• Warfarin remains a primary agent for stroke prevention in high-risk AF populations.
• Rate control agents are effective for managing ventricular response in AF, with specific indications for propranolol.